L. Roll

2.5k total citations · 1 hit paper
8 papers, 1.9k citations indexed

About

L. Roll is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, L. Roll has authored 8 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 3 papers in Surgery. Recurrent topics in L. Roll's work include Pancreatic and Hepatic Oncology Research (5 papers), Cancer Genomics and Diagnostics (3 papers) and Gastric Cancer Management and Outcomes (3 papers). L. Roll is often cited by papers focused on Pancreatic and Hepatic Oncology Research (5 papers), Cancer Genomics and Diagnostics (3 papers) and Gastric Cancer Management and Outcomes (3 papers). L. Roll collaborates with scholars based in Germany. L. Roll's co-authors include Hanno Riess, Helmut Oettle, Bernd Doerken, J. Fahlke, Karsten Ridwelski, P. Neuhaus, Wolf O. Bechstein, Ingo Schmidt‐Wolf, Carl Zuelke and Christof Burkart and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Oncology Research and Treatment.

In The Last Decade

L. Roll

8 papers receiving 1.8k citations

Hit Papers

Adjuvant Chemotherapy With Gemcitabine vs Observation in ... 2007 2026 2013 2019 2007 500 1000 1.5k

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
L. Roll Germany 4 1.7k 736 665 650 530 8 1.9k
Bernd Doerken Germany 10 1.8k 1.0× 729 1.0× 661 1.0× 672 1.0× 509 1.0× 19 2.1k
Karin Weigang-Koehler Germany 5 1.8k 1.0× 719 1.0× 632 1.0× 614 0.9× 486 0.9× 9 1.9k
Christof Burkart Germany 5 1.7k 1.0× 748 1.0× 629 0.9× 648 1.0× 493 0.9× 6 1.8k
Pamela J. Hodul United States 28 2.0k 1.1× 805 1.1× 743 1.1× 811 1.2× 423 0.8× 91 2.3k
Shoichi Hishinuma Japan 16 1.4k 0.8× 797 1.1× 493 0.7× 604 0.9× 337 0.6× 47 1.6k
Jörg Fahlke Germany 9 1.3k 0.8× 732 1.0× 394 0.6× 650 1.0× 421 0.8× 21 1.6k
Marianne Sinn Germany 15 1.6k 0.9× 673 0.9× 435 0.7× 601 0.9× 558 1.1× 49 1.8k
H Schramm Germany 9 2.1k 1.2× 1.1k 1.4× 715 1.1× 785 1.2× 551 1.0× 42 2.5k
Stefano Cereda Italy 21 1.1k 0.6× 564 0.8× 311 0.5× 535 0.8× 323 0.6× 53 1.5k
Francesco Minni Italy 30 1.7k 1.0× 1.4k 1.9× 557 0.8× 887 1.4× 272 0.5× 137 2.6k

Countries citing papers authored by L. Roll

Since Specialization
Citations

This map shows the geographic impact of L. Roll's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Roll with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Roll more than expected).

Fields of papers citing papers by L. Roll

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. Roll. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Roll. The network helps show where L. Roll may publish in the future.

Co-authorship network of co-authors of L. Roll

This figure shows the co-authorship network connecting the top 25 collaborators of L. Roll. A scholar is included among the top collaborators of L. Roll based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. Roll. L. Roll is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Pelzer, Uwe, Jens Stieler, L. Roll, et al.. (2009). Second-Line Therapy in Refractory Pancreatic Cancer. Results of a Phase II Study. Oncology Research and Treatment. 32(3). 99–102. 27 indexed citations
2.
Hilbig, Andreas, Uwe Pelzer, Jens Stieler, et al.. (2008). Decrease of CA 19–9 in patients with advanced pancreatic cancer (APC) undergoing chemotherapy predicts survival time. Journal of Clinical Oncology. 26(15_suppl). 15574–15574. 3 indexed citations
3.
Oettle, Helmut, Stefan Post, P. Neuhaus, et al.. (2007). Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer. JAMA. 297(3). 267–267. 1754 indexed citations breakdown →
4.
Pelzer, Uwe, Andreas Hilbig, Jens Stieler, et al.. (2006). A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT - CONKO 004). Journal of Clinical Oncology. 24(18_suppl). 4110–4110. 26 indexed citations
5.
Oettle, Helmut, Uwe Pelzer, Jens Stieler, et al.. (2005). Oxaliplatin/folinic acid/5-fluorouracil [24h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003). Journal of Clinical Oncology. 23(16_suppl). 4031–4031. 66 indexed citations
6.
Hilbig, Andreas, Jens Stieler, Uwe Pelzer, et al.. (2004). Phase II study of gemcitabine, cisplatin, folinic acid (FA) and infusional 5-fluorouracil (5-FU) in patients with inoperable esophageal cancer (IEC). Journal of Clinical Oncology. 22(14_suppl). 4238–4238. 1 indexed citations
7.
Stieler, Jens, Andreas Hilbig, Uwe Pelzer, et al.. (2004). Gemcitabine, oxaliplatin, 5-FU and folinic acid as an outpatient first-line therapy in patients with inoperable esophageal cancer: A phase I study. Journal of Clinical Oncology. 22(14_suppl). 4250–4250. 1 indexed citations
8.
Roll, L.. (1953). Ulceration of the bronchial stump after resection for tuberculosis.. PubMed. 49(1). 205–7. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026